IGC Pharma
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell IGC Pharma and other ETFs, options, and stocks.About IGC
IGC Pharma, Inc. is a clinical-stage pharmaceutical company that is focused on Alzheimer's disease, developing innovative solutions to address this devastating illness. It has two investigational drug assets targeting Alzheimer's disease: IGC-AD1, which is in a Phase 2 clinical trial as a treatment for agitation in dementia due to Alzheimer's and TGR-63 that is in pre-clinical development.
CEORam Mukunda
CEORam Mukunda
Employees70
Employees70
HeadquartersPotomac, Maryland
HeadquartersPotomac, Maryland
Founded2005
Founded2005
Employees70
Employees70
IGC Key Statistics
Market cap35.47M
Market cap35.47M
Price-Earnings ratio-4.86
Price-Earnings ratio-4.86
Dividend yield—
Dividend yield—
Average volume1.16M
Average volume1.16M
High today$0.3995
High today$0.3995
Low today$0.3846
Low today$0.3846
Open price$0.3958
Open price$0.3958
Volume564.37K
Volume564.37K
52 Week high$0.4985
52 Week high$0.4985
52 Week low$0.2525
52 Week low$0.2525
Stock Snapshot
With a market cap of 35.47M, IGC Pharma(IGC) trades at $0.39. The stock has a price-to-earnings ratio of -4.86.
On 2025-11-06, IGC Pharma(IGC) stock moved within a range of $0.38 to $0.40. With shares now at $0.39, the stock is trading +0.3% above its intraday low and -3.5% below the session's peak.
Trading volume for IGC Pharma(IGC) stock has reached 564.37K, versus its average volume of 1.16M.
The stock's 52-week range extends from a low of $0.25 to a high of $0.50.
The stock's 52-week range extends from a low of $0.25 to a high of $0.50.
IGC News
TipRanks 3d
IGC Pharma expands AI-powered in-Silico drug discovery platformIGC Pharma (IGC) announced an expansion of its AI-powered in-Silico drug discovery platform. The company is now integrating more methodologies, including retros...
People also own
Based on the portfolios of people who own IGC. This list is generated using Robinhood data, and it’s not a recommendation.